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Aims: To evaluate the impact adoption of the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) criteria on prevalence of gestational diabetes mellitus
(GDM) and risks of perinatal outcomes.
Methods: Retrospectively, 155,103 women screened with selective two step criteria in
Switzerland in period 1 (2005–2010) were compared to 170,427 women screened with
IADPSG criteria in period 2 (2012–2017). GDM prevalence over time was established and
multivariable regression used to assess variation in risks for GDM related events and peri-
natal outcomes.
Results: GDM prevalence increased steadily over both study periods from 1.8% to 9.0%. A
risk reduction of GDM-related events was shown only for women with one or two risk fac-
tors for GDM present (relative risk (95% confidence interval)): (0.93 (0.90,0.97), 0.90
(0.83,0.96)). The comparison of perinatal outcomes between the two study periods revealed
a significant lower risk for newborns large for gestational age (LGA) (0.93 (0.91–0.95)), pre-
term delivery (0.94 (0.92–0.97)) and neonatal hypoglycemia (0.83 (0.77–0.90)) in period 2.
Conclusion: The introduction of the IADPSG criteria for the screening of GDM increased
prevalence by threefold with no substantial improvements in GDM related events for
women without risk factors but reduced the risks for LGA, neonatal hypoglycemia and pre-
term birth.
 2021 The Author(s). Published by Elsevier B.V. This is an open access articleunder theCCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gestational diabetes mellitus (GDM) is defined as glucose
intolerance resulting in hyperglycemia with onset or first
recognition during pregnancy [1]. Its prevalence is rapidly
increasing due to obesity epidemics, older age at pregnancy
and more sedentary lifestyle. It ranges between 7 and 10%
of all pregnancies worldwide according to different GDM diag-nostic criteria [2–5]. In Switzerland estimates showed an aver-
age of 5.1% of total women diagnosed with GDM since 2005
[6].
Overt diabetes mellitus in pregnancy is highly associated
with risks of adverse perinatal outcomes and health compli-
cations later in life [7]. It is therefore important to screen
and identify women at risk for GDM and ensure effective
and appropriate treatment. Although, detection of GDM in
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 3 0pregnancy is essential for the wellbeing of mother and baby,
screening strategies, methods and even diagnostic optimum
of glycemic thresholds for GDM remain subject of controver-
sial debate [8].
While GDM was initially defined based on the maternal
risk for developing postpartum diabetes, it was subsequently
adapted by taking in consideration the adverse maternal and
neonatal outcomes [5]. The study of the Hyperglycemia and
Adverse Pregnancy Outcomes (HAPO) showed a continuous
and linear association between increasing level of maternal
blood glucose on a 75 g oral glucose tolerance test (OGTT)
and adverse pregnancy outcomes. GDM diagnostic criteria
were therefore set on the odds ratio (OR) of 1.75 for specific
outcomes, relative to their mean [7]. Based on this findings,
the International Association of Diabetes and Pregnancy
Study Groups (IADPSG) issued recommendations of a GDM
screening strategy using a universal one-step 75 g OGTT
between 24 and 28 weeks of gestation [9].
The new IADPSG screening strategy has been topic of
extensive debate, as a rise in incidence of GDM and an
increased burden on a number of health care systems were
shown [10–12]. Even though, by adopting the IADPSG screen-
ing criteria, cost savings and improved pregnancy outcomes
have been found in some studies [13,14], others did not find
similar benefits [15,16]. This former switch from a risk-
based to a universal GDM screening recommended by the
IADPSG has been also criticized for contributing to a medical-
ization of previously healthy pregnancies, with potential
implications on women’s quality of life [10]. Consequently,
European countries such as France, Italy and Ireland adopted
the IADPSG criteria only in women with GDM risk factors
[17,18]. Such a selective screening leads to a concentration
of diagnostic efforts being made on women in risk of acquir-
ing GDM but has been shown to miss up to 40% of cases
[12,19].
With the ongoing debate about the implementation of the
IADPSG strategy, there is a need for updates to gain a clear
understanding about benefits and challenges of the adopting
the new screening criteria. This study will take advantage of a
large Swiss cohort to examine the influence of implementing
the IADPSG screening strategy on prevalence of GDM and
perinatal outcomes in women screened for GDM. Further-
more, the contribution by risk factors will be evaluated that
might affect GDM-related events while comparing IADPSG
to priori screening.
2. Research design and methods
2.1. Participants
The present study retrospectively analyzed anonymized data
from 325,530 women in Switzerland who delivered singleton
infants between 22 and 43 weeks of gestational from January
1, 2005 to December 31, 2017. Excluded were women with
known type 1 or type 2 diabetes mellitus. Information on
deliveries were retrieved from the Swiss obstetric study group
database for obstetric and gynecological hospital admissionas described in Aubry et al., 2019 [6]. Briefly, the group system-
atically records details about delivery admission, birth and
discharge of all women from more than 100 Swiss obstetrics
hospitals of various sizes and structures [20]. Data were col-
lected using a two-step control system. The quality and com-
pleteness were firstly verified by a senior physician at the
time of discharge and secondly by an independent quality
control group. In case of data discrepancy, the hospitals were
asked to verify and correct data. Items in the database con-
tain the International Statistical Classification of Diseases
and Related Health Problems, 10th Revision (ICD-10) codes.
Data for this study were extracted by removing all informa-
tion related to a patient’s identification. Because data were
anonymized and irreversibly de-identified, this study did
not need approval from the Swiss ethics committee, accord-
ing to the Swiss Federal Act on Research involving Human
Being (810.30, Art. 2, 2) [21].
2.2. Screening methods and management of women with
GDM
During period 1 (2005–2010), women were selectively screened
based on risk factors for GDM and diagnosed with the two-
step approach: usually, after 12 h of fasting, a 50 g oral glucose
challenging test was performed. If glycemia after one hour
was greater than 7.2 mmol/l, a 75 g or 100 g OGTTwas carried
out [22]. A GDM diagnosis was given with at least two values
equal to or above the thresholds 5.3 mmol/l fasting,
10.0 mmol/l at 1 h, 8.6 mmol/l at 2 h or 7.8 mmol/l at 3 h. How-
ever, the use of alternative defined OGTT thresholds were at
the discretion of caregivers [23].
During period 2 (2012–2017), women were screened by
switching gradually to the IADPSG criteria: a 75 g OGTTwas
performed on all women after an overnight fast. A GDM diag-
nosis was confirmed if one value was equal to or above the
following thresholds: 5.1 mmol/l fasting, 10.0 mmol/l at 1 h,
8.5 mmol/l at 2 h [24]. In both periods, women underwent
screening between the 24 and 28 weeks gestational age or
later if it was not possible before.
Follow up treatment protocols were similar between the
two periods: Women diagnosed with GDM were referred to a
multidisciplinary team including obstetricians, midwifes, dia-
betologists, dietitians, and nurse educators for glucose moni-
toring, treatment initiation, nutritional and lifestyle therapy.
Regular check-ups to maintain optimal glycemic control were
carried out by the primary gynecologist and if necessary,
insulin treatment was introduced. In case of complications
from GDM, women were referred to a secondary level care
setting.
2.3. Risk factors, GDM-related events, and perinatal
outcomes
Women were considered at risk for GDM if at least one of the
following criteria was fulfilled: maternal age over 35, preges-
tational BMI over 30 kg/m2, multiple gestations, conception
by assisted reproductive technology, smoking during
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 3 0 3pregnancy, chronic hypertension, priori macrosomia or non-
Caucasian origin.
The following ICD-10 diagnoses were assigned to
GDM-related events: pre-eclampsia (blood
pressure  140/90 mmHg with proteinuria of at least
0.3 g/24 h) (O14, O14.1), large-for-gestational-age infant
(birthweight > 90th percentile according to Nicolaides et al.,
2018 [25], obstructed labor due to shoulder dystocia (O66.0),
transitory neonatal hypoglycemia (<2 mmol/L) (P70.4).
All other perinatal outcomes were defined as the following
(ICD-10 codes in brackets): induction of labor (physical, sys-
temic/vaginal prostaglandin use), cesarean delivery (primary,
secondary and elective cesarean section) (O82), instrumental
vaginal delivery methods (vacuum extraction and forceps)
(O81), small-for-gestational-age infant (birthweight < 10th
percentile according to Nicolaides et al., 2018) [25], neonatal
intensive care unit admission (NICU admission), respiratory
distress of newborn (P22.9), stillbirth and infant death up to
seven days post-partum (P95) were defined as early neonatal
death [26], preterm delivery (<37 weeks of gestation).
2.4. Statistical analysis
To examine how the prevalence of GDM developed before and
after the adoption of the IADPSG screening criteria, the
annual frequency of GDM diagnoses was calculated and
adjusted for maternal age, pre-pregnancy BMI  30 kg/m2,
parity, history of smoking during pregnancy, and Caucasian
origin. GDM prevalence, GDM-related events and perinatal
outcomes were analyzed by comparing data in period 1
(2005–2010) and period 2 (2012–2017), i.e. six years before
and after the implementation of the IADPSG screening crite-
ria in Switzerland. The year of the introduction of the new cri-
teria (2011) was not included in the analysis. Estimates for
relative risks (RR) and 95% confidence intervals (CI) associated
with this implementation were derived from multivariable
logistic regression for outcomes with a prevalence < 10%
and multivariable poisson regression for outcomes with a
prevalence  10% [27]. All analyses were performed using R
version 3.4 [28].
3. Results
In this analysis a total of 325,530 pregnant women were
included, with 155,103 in period 1 and 170,427 in period 2.
Even though women in both periods were comparable, there
were slightly fewer smokers in period 2 (5.8% vs. 6.2%;
p < 0.001) and fewer women with pregestational BMI over
30 kg/m2 (6.8% vs. 7.4%; p < 0.001). Women in period 2 were
also slightly older. The prevalence of GDM in period 2 was
three times higher (8.3% vs. 2.7%; p < 0.001) when compared
to the first period (Table 1).
The prevalence of GDM over the whole study period is pre-
sented in Fig. 1. The prevalence of GDM increased steadily
over both study periods from 1.8% to 9.0%, while showing
the greatest increase between 2010 and 2012 from 3.3% to
5.9%. GDM prevalence during the study period showed similar
trends when adjusted.The presence of either one or multiple risk factors was
associated with a higher rate of GDM and of GDM-related
events in both periods (Fig. 2). Relative risks calculated for
each level of risk factor revealed a stronger effect of period
(1 vs. 2) on GDM prevalence in women without risk factors
(1.4% vs. 5.3%; RR 3.75 (CI 3.54,3.99)) than in women with 3
or more risk factors present (12.5% vs. 28.4%; RR 2.28 (CI
1.84,2.84)) (Fig. 2 A). The opposite pattern could be observed
for GDM-related events, where the new screening criteria
had no effect in women without risk factors (9.8% vs. 9.6%;
RR 0.98 (CI 0.95,1.01)) but a small effect in women with one
or two risk factors present (RR 0.93 (CI 0.90,0.97), RR 0.90 (CI
0.83,0.96)) (Fig. 2B).
A comparison of perinatal outcomes between the two
study periods is shown in Table 2. While relative risk of labor
outcomes strongly related to GDM such as shoulder dystocia
(RR 1.16 (1.06–1.26)) and cesarean section (RR 1.04 (1.02–
1.05)) were increased from period 1 to period 2, no significant
difference was found for preeclampsia (RR 0.99 (0.93–1.05)).
Furthermore, for the neonatal outcomes: the number of new-
borns large for gestational age, pre-term delivery and neona-
tal hypoglycemia, all three outcomes associated with GDM,
significantly decreased from study period 1 to period 2 (LGA:
RR 0.93 (0.91–0.95), preterm birth: RR 0.94 (0.92–0.97), neonatal
hypoglycemia: RR 0.83 (0.77–0.90)). However, no positive effect
could be observed for other outcomes typically associated
with GDM, for example respiratory distress or neonatal inten-
sive care unit admission.
4. Discussion
The new IADPSG recommendation for screening of GDM was
implemented in Switzerland in 2011 to standardize screening
procedure for all pregnant women [24]. The new criteria allow
a more strict and sensitive screening that include all pregnant
women, regardless of their predisposition to GDM. However,
the more stringent criteria have been reported to rise preva-
lence and potentially increase the cost of care [29,30]. In the
current study, we observed that the prevalence of GDM
increased by more than a factor of 4 from 2005 to 2017, and
by 3 comparing the two study periods. This rise of prevalence
is in line with previous studies after the new criteria were
adopted [11,31,32]. In Spain, GDM prevalence increased 3.3
times (10.6–35.5%), in the USA 2.8 times (5.5–15.6%) and 4.5
times in Japan (2.9–13%) using the IADPSG criteria [13,33,34].
A large increase in GDM prevalence can also be attributed to
other factors, however, we observed a similar pattern in our
data when controlling for maternal age, pre-pregnancy obe-
sity and other relevant population characteristics. Moreover,
the largest increase occurred during the period of implemen-
tation of the new criteria. Therefore, it is reasonable to
assume that the increase in GDM prevalence is at least partly
due to the adoption of the new diagnostic criteria, potentially
as the more sensitive and less selective testing includes more
womenwith no risk factors and less severe forms of GDM [35].
Although, the HAPO study confirmed that GDM related
complications correlate in a continuous fashion with levels
of maternal hyperglycemia there is no conclusive evidence
Fig. 1 – Prevalence of gestational diabetes in women with singleton deliveries in Switzerland from 2005 to 2010 (period 1).
Unadjusted prevalence (black line) and prevalence adjusted for maternal age, pre-pregnancy BMI  30 kg/m2, smoking during
pregnancy, and Caucasian origin (grey line).
Table 1 – Baseline characteristics. Data are mean ± SD or count (%). Period 1 (2005–2010) and period 2 (2012–2017).
Characteristics period 1 period 2 p-value
N = 155103 N = 170427
Maternal age (years) 30.7 (5.18) 31.5 (4.94) <0.001
Parity <0.001
1 74162 (47.8%) 83,061 (48.7%)
2 55,437 (35.7%) 61,489 (36.1%)
3 19,185 (12.4%) 19,885 (11.7%)
4+ 6319 (4.1%) 5992 (3.5%)
Birth weight in gram 3352 (516) 3350 (512) 0.316
Caucasian origin 143,446 (92.5%) 157,419 (92.4%) 0.210
Pre-pregnancy BMI  30 kg/m2 11,531 (7.4%) 11,556 (6.8%) <0.001
Smoking during pregnancy 9612 (6.2%) 9913 (5.8%) <0.001
Gestational diabetes mellitus 4259 (2.7%) 14,147 (8.3%) <0.001
Without risk factors for GDM 91,281 (58.8%) 97,113 (57.0%) 0.160
4 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 3 0yet if screening also women without risk factors and treating
milder cases leads to better perinatal outcomes [7,36,37]. A
recent Swiss study by Gariani et al., 2019 observed signifi-
cantly greater number of women who could achieve a good
glycemic control without the need for insulin therapy with
the use of the new criteria. However, there was no difference
in the occurrence of most adverse perinatal outcomes associ-
ated with milder GDM cases [35]. Slightly more than half of
the women in our population exhibited of no risk factor for
GDM and were included in the screening by adopting the
IADPSG criteria. Nevertheless, despite substantial increase
in GDM testing in this population, and almost four times
more women without risk factors diagnosed, treating those
women did not translate in better pregnancy outcomes. Over-
all, the number of risk factors is clearly associated with GDM
prevalence and the risk for GDM-related events. It was sug-
gested that multiple risk factors would be very specific for
GDM screening in selective approaches [38]. Interestingly,
however, our study shows that in period 2 frequency andrelative risks of GDM related events are slightly reduced with
increased GDM risk factors pre-disposition. This may suggest
that not identifying women with GDM because they were not
eligible to screening might not be as detrimental as missing
out cases of women with risk factors suffering from mild
hypoglycemia. A study of Hung et al. showed that risk factors
for GDM differ with the diagnostic criteria used [14]. They
assumed that with lower thresholds for GDM diagnosis
women with mild glucose intolerance triggered by other
metabolic disorders and previously regarded as not having
diabetes by the two-step were identified with the one-step
method used by the IADPSG criteria [14]. Including and treat-
ing more mild cases of hypoglycemia in Switzerland with the
new criteria slightly reduced GDM related events only in
women with risk factors. Therefore, it could be argued that
linearity of relationship between adverse outcomes and gly-
cemia and thresholds set at OR1.75 by the HAPO study might
differ with risk factor predisposition of the screened popula-
tion [7].
Fig. 2 – Prevalence of gestational diabetes in pregnancy (A) and GDM-related events (B) by the number of risk factors for GDM
in period 1 (2005–2010, black) and period 2 (2012–2017, grey). For each level of risk factors present (0, 1, 2, 3), data are % or
relative risks (RR) with 95% confidence intervals (CI) for changes in period 2 vs period 1. GDM-related events included at least
one of the following diagnosis: preeclampsia, shoulder dystocia, neonatal hypoglycemia, large-for-gestational age infants.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 3 0 5Nevertheless, a recent meta-analysis of randomized con-
trolled trials provided evidence that the one step approach
significantly improves perinatal outcomes independently of
risk factors [39]. Their main findings were a reduction of
54% in LGA, 51% in NICU admission, 48% in neonatal hypo-
glycemia. Consistently, we showed that women screened
with the one step approach had a slightly decreased risk of
neonatal outcomes linked to GDM, including LGA, neonatal
hypoglycemia und preterm birth. However, no significant
changes in the risk reduction of NICU admission were found.
It is likely that including more mild cases in a GDM therapy
not requiring insulin by adjusting maternal diet and physical
activity, may results in fewer newborns having LGA or neona-
tal hypoglycemia but would be less effective on other labor
outcomes [40].
Several other observational studies have explored the
changes in perinatal outcomes associated with hyper-
glycemia during two successive periods of time [31,32,41–43].
But few studies exhibit of a large enough sample size to detect
changes in adverse perinatal outcomes by comparing the
total population. In Japan, despite a substantial rise in GDMdiagnosis frequency from 2.9% to 13%, a significantly
decreased odds were only observed for NICU admission and
neonatal hypoglycemia [34]. With a similar change in GDM
prevalence (2.6% vs. 9.7%), the introduction of the IADPSG cri-
teria resulted in reduction in incidences of LGA, macrosomia
and hypertensive disorders in Slovenian pregnant women
[43].
Although some studies show slight improvements in
selected perinatal outcomes it remains unclear whether these
improvements can counterbalance the costs of treating more
pregnant women with milder hyperglycemia. In this study,
the prevalence of GDM almost quadrupled in the large group
of women without risk factors, with no reduction in the num-
ber of GDM-related events. By contrast, Duran et al. con-
cluded that the IADPSG criteria resulted in a significant
decrease of multiple adverse perinatal outcomes [13]. In par-
ticular, reductions of frequency in NICU admission and cesar-
ean deliveries accounted for cost effectiveness over increased
GDM prevalence [13]. However, it should be noted that GDM
prevalence (35.5%) and risk factors occurrence in this Spanish
population were particularly high compared to those reported
Table 2 – Comparison of perinatal outcomes of period 1 (2005–2010)and period 2 (2012–2017). Data are n (%) or adjusted relative risks (RR) with 95% confidence intervals (CI)
for changes after the implementation of the IADPSG criteria (period 1/period 2) and the association of perinatal outcomes to GDM during (period 1 and period 2 combined/
GDM). Poisson (prevalence  10%) or logistic (prevalence < 10%,) models adjusted for maternal age, pre-pregnancy BMI  30 kg/m2, ethnicity, parity and smoking during
pregnancy.  additionally adjusted for cesarean section.
Outcomes period 1 period 2 period 1/period 2 period 1 and period 2 combined/ GDM
N = 155103 N = 170427 RR (95% CI) p RR (95% CI) p
Comorbidities
preeclampsia 1884 (1.21%) 2047 (1.20%) 0.99 (0.93–1.05) 0.6413 1.17 (1.04–1.31) 0.0108
Labor outcomes
Instrumental vaginal delivery 18,125 (11.7%) 19,459 (11.4%) 0.95 (0.93–0.97) <0.001 1.00 (0.96–1.06) 0.8437
Induction of labor 30,207 (19.5%) 32,352 (19.0%) 0.98 (0.97–1.00) 0.0470 1.69 (1.64–1.74) <0.001
Cesarean section 43,159 (27.8%) 50,551 (29.7%) 1.04 (1.02–1.05) <0.001 1.17 (1.14–1.20) <0.001
Epidural anesthesia 41,620 (26.8%) 48,307 (28.3%) 1.05 (1.04–1.07) <0.001 1.04 (1.01–1.08) 0.0042
Fetal heart rate abnormality 34,840 (22.5%) 42,169 (24.7%) 1.08 (1.07–1.10) <0.001 1.02 (0.99–1.16) 0.1623
Prolonged labor 9890 (6.4%) 13,994 (8.2%) 1.28 (1.25–1.31) <0.001 1.01 (0.96–1.07) 0.7179
Failure to progress in labor 10,059 (6.5%) 10,573 (6.2%) 0.92 (0.90–0.95) <0.001 1.02 (0.96–1.08) 0.5420
Shoulder dystocia 1000 (0.6%) 1245 (0.7%) 1.16 (1.06–1.26) <0.001 1.68 (1.44–1.94) <0.001
Neonatal outcomes
LGA 14,857 (9.6%) 14,930 (8.8%) 0.93 (0.91–0.95) <0.001 1.43 (1.38–1.48) <0.001
SGA 17,158 (11.1%) 19,007 (11.2%) 1.00 (0.98–1.02) 0.7628 0.87 (0.83–0.92) <0.001
50 Apgar score  7 7613 (4.9%) 10,187 (6.0%) 1.21 (1.17–1.24) <0.001 1.10 (1.03–1.17) 0.0035
Neonatal hypoglycemia (<2 mmol/L) 1184 (0.8%) 1193 (0.6%) 0.83 (0.77–0.90) <0.001 2.68 (2.37–3.02) <0.001
Respiratory distress of newborn 6106 (4.0%) 7544 (4.4%) 1.11 (1.08–1.15) <0.001 1.27 (1.18–1.35) <0.001
Intensive care unit admission 6681 (4.3%) 7359 (4.3%) 0.99 (0.96–1.02) 0.6185 1.28 (1.20–1.37) <0.001
Early neonatal death 702 (0.5%) 677 (0.4%) 0.87 (0.78–0.97) 0.0089 0.76 (0.57–0.97) 0.0379















































d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 5 ( 2 0 2 1 ) 1 0 8 8 3 0 7in our and other studies study population [32,34,41,43]. Con-
clusively, countries with high GDM prevalence and risk factor
burden might benefit most from adopting of the IADPSG
screening criteria to substantially improve perinatal out-
comes to an extent of being able to ignore the drawbacks of
increased medical cost. Further investigations will be needed
to examine this cost benefit standpoint.
The strength of this study is that we retrieved data from a
large sample size involving no less than 30% of all women
that have giving birth in Switzerland over 12 years. However,
a limitation of this study is that although, we included known
confounders in our statistical models, there is still the possi-
bility that other factors may have influenced the outcome
over time and the effects cannot be solely attributed to the
introduction of the new IADPSG screening strategy. Moreover,
our study is limited to the analysis of perinatal outcomes,
improvements in long term health of both mother and child
that would be a second aim of GDM treatment was not exam-
ined. Furthermore, uniformly defined and standardized GDM
screening in Switzerland was missing before the introduction
of the IADPSG recommendation in 2011. Therefore, in this
study we cannot determine the impact of different glucose
values thresholds with the new criteria. However, before
2011, all clinics in Switzerland had performed according to a
risk-based two-step GDM diagnostic procedure with two val-
ues over the threshold needed for diagnosis.
We conclude that in our sample, implementing IADPSG
criteria resulted in a significant reduction of risks for LGA,
neonatal hypoglycemia and preterm birth. However, there
was no substantial improvement in GDM-related events for
women without risk factors with the adoption of the new cri-
teria, but up to a threefold increase in GDM prevalence. Nev-
ertheless, we showed that women with risk factors might
slightly benefit from a more sensitive screening.
Further research will be required to determine the validity
of the IADPSG diagnostic criteria in Switzerland from a cost
benefit perspective.
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